Roche pens third pact of the week in $66M up­front to MO­MA Ther­a­peu­tics

Roche is off to the races in 2024, with the Swiss Big Phar­ma ink­ing its third biotech col­lab­o­ra­tion this year on Thurs­day morn­ing.

As part of a five-year, $66 mil­lion up­front tie-up, Roche and MO­MA Ther­a­peu­tics will work to­geth­er to de­vel­op up to six new pre­ci­sion on­col­o­gy pro­grams.

Roche al­ready an­nounced an an­ti­body-drug con­ju­gate deal with a Chi­nese biotech and an RNA pro­cess­ing pact with Remix Ther­a­peu­tics ear­li­er this week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER